Views & Analysis Patient power in Europe – more work to be done What the EMA and pharma can do to promote patient involvement in decision making.
News Brexit could delay drug launches, former MHRA chief warns Britain will be in "second or third tier" of drug launches, experts warn.
News Could UK's post-Brexit regulator evaluate value as well? But longer-term benefits could include faster reimbursement decisions.
News Hunt under pressure over plans to quit EMA Britain could be in "second rank" of medicines access, warn MPs.
News EU drug regulators concerned about Brexit impact European regulators concerned over impact of EMA move.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
